Weekly Analysts’ Ratings Updates for Roivant Sciences (ROIV)

A number of research firms have changed their ratings and price targets for Roivant Sciences (NASDAQ: ROIV):

• 5/26/2026 – Roivant Sciences had its price target raised by Guggenheim from $30.00 to $36.00. They now have a “buy” rating on the stock.
• 5/22/2026 – Roivant Sciences was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 5/21/2026 – Roivant Sciences had its “overweight” rating reaffirmed by Piper Sandler.
• 5/21/2026 – Roivant Sciences had its price target raised by TD Cowen from $38.00 to $41.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Roivant Sciences had its price target raised by Citigroup Inc. from $35.00 to $42.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Roivant Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $34.00 price target on the stock.
• 5/21/2026 – Roivant Sciences was given a new $42.00 price target by Leerink Partners.
• 5/8/2026 – Roivant Sciences had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 4/16/2026 – Roivant Sciences had its price target raised by Piper Sandler from $22.00 to $40.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Roivant Sciences

In related news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer directly owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 945,173 shares of company stock valued at $27,654,456 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.